High nuclear grade, frequent mitotic activity, cyclin D1 and p53 overexpression are associated with stromal invasion in mammary intracystic papillary carcinoma

Breast Journal

Volumn 11, Issue 1, 2005, Pages 2-8

  Zhang, Cunxian ^a   Zhang, Peng ^a   Hao, Jie ^a   Quddus, M Ruhul ^a   Steinhoff, Margaret M ^a   Sung, C James ^a  

^a RHODE ISLAND HOSPITAL   (United States)

Author keywords

Core needle biopsy; Intracystic papillary carcinoma; Stromal invasion

Indexed keywords

CYCLIN D1; EOSIN; HEMATOXYLIN; MONOCLONAL ANTIBODY; PROTEIN P53;

ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CELL NUCLEUS; CONTROLLED STUDY; CORE NEEDLE BIOPSY; CYCLIN D1 GENE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; EXCISION; FEMALE; FIBROCYSTIC BREAST DISEASE; FISHER EXACT TEST; GENE; GENE OVEREXPRESSION; HEMATOXYLIN EOSIN STAINING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAMMARY INTRACYSTIC PAPILLARY CARCINOMA; MITOSIS RATE; NEEDLE BIOPSY; PAPILLARY CARCINOMA; STAINING; STATISTICAL SIGNIFICANCE; STROMA; TISSUE SECTION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MITOTIC INDEX; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 13444268941     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1075-122X.2005.21533.x     Document Type: Article

References (23)

1. Czernobilsky B. Intracystic carcinoma of the female breast. Surg Gynecol Obstet 1967;124:93-98.
2. Carter D. Intraductal papillary tumors of the breast. A study 78 cases. Cancer 1977;39:1689-92.
3. Devitt JE, Barr JR. The clinical recognition of cystic carcinoma of the breast. Surg Gynecol Obstet 1984;159:130-32.
4. Rosen PP. Papillary carcinoma. In: Rosen PP, ed. Rosen's Breast Pathology, 2nd ed. Philadelphia: Lippincott-Williams & Wilkins, 2001:381-404.
5. Tavassoli FA. Papillary lesions. In: Pathology of the Breast. Stamford, CT: Appleton and Lange, 1999:325-71.
6. Carter D, Orr SL, Merino MJ. Intracystic papillary carcinoma of the breast. After mastectomy, radiotherapy or excisional biopsy alone. Cancer 1983;52:14-19.
7. Lefkowitz M, Lefkowitz W, Wargotz ES. Intraductal (intracystic) papillary carcinoma of the breast and its variants: a clinicopathological study of 77 cases. Hum Pathol 1994;25:802-9.
8. Harris KP, Faliakou EC, Exon DJ, et al. Treatment and outcome of intracystic papillary carcinoma of the breast. Br J Surg 1999;86:1274.
9. Leal C, Costa I, Fonseca D, et al. Intracystic (encysted) papillary carcinoma of the breast: a clinical, pathological, and immunohistochemical study. Hum Pathol 1998;29:1097-104.
10. Solorzano CC, Middleton LP, Hunt KK, et al. Treatment and outcome of patients with intracystic papillary carcinoma of the breast. Am J Surg 2002;184:364-68.
11. Rietman JS, Dijkstra PU, Geertzen JH, et al. Shot-term morbidity of the upper limb after sentinel lymph node biopsy or axillary lymph node dissection for stage I or II breast carcinoma. Cancer 2003;98:690-96.
12. Schijven MP, Vingerhoets AJ, Rutten HJ, et al. Comparison of morbidity between axillary lymph node dissection and sentinel node biopsy. Eur J Surg Oncol 2003;29:341-50.
13. Strauss M, Lukas J, Bartek J. Unrestricted cell cycling and cancer. Nat Med 1995;1:1245-46.
14. Dickson C, Fantl V, Gillett C, et al. Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer Lett 1995;90:43-50.
15. Bartkova J, Lukas J, Muller H, et al. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 1994;57:353-61.
16. Gillett C, Fantl V, Smith R, et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994;54:1812-17.
17. McIntosh GG, Anderson JJ, Milton I, et al. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 1995;11:885-91.
18. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001;411:1017-21.
19. Isola J, Visakorpi T, Holli K, Kallioniemi OP. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast-cancer patients. J Natl Cancer Inst 1992;84:1109-14.
20. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-206.
21. Saddik M, Lai R, Medeiros LJ, McCourty A, Brynes K. Differential expression of cyclin D1 in breast papillary carcinomas and benign papillomas: an immunohistochemical study. Arch Pathol Lab Med 1999;123:152-56.
22. Lanzafame S, Emmanuele C, Torrisi A, Magro G. Correlated expression of BCL-2 protein, estrogen receptor, cathepsin D and low growth fraction (PCNA) in intracystic papillary breast carcinoma. Pathol Res Pract 1998;194:541-47.
23. Zhang C, Zhang P, Sung CJ, Lawrence WD. Over-expression of p53 is correlated with stromal invasion in extramammary Paget's disease of the vulva. Hum Pathol 2003;34:880-85.